Get the Stockscreener App
7.74
2.25%
0.17
Fennec Pharmaceuticals Inc stock is traded at $7.74, with a volume of 74,018.
It is up +2.25% in the last 24 hours and down -3.25% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$7.57
Open:
$7.58
24h Volume:
74,018
Relative Volume:
0.66
Market Cap:
$264.35M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-12.69
EPS:
-0.61
Net Cash Flow:
$-17.14M
1W Performance:
-1.90%
1M Performance:
-3.25%
6M Performance:
+0.85%
1Y Performance:
+27.51%
1-Day Range:
$7.47
$7.78
1-Week Range:
$7.3501
$8.25
52-Week Range:
$4.68
$9.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
7.74 | 258.54M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Can Fennec Pharmaceuticals Inc. (RV41) stock withstand sector downturns2025 Trade Ideas & Expert Verified Stock Movement Alerts - Newser
How analysts revise price targets for Fennec Pharmaceuticals Inc. (RV41) stockJuly 2025 Breakouts & Safe Entry Point Identification - Newser
(FENC) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Will Fennec Pharmaceuticals Inc. (RV41) stock benefit from Fed rate cutsDay Trade & Smart Allocation Stock Reports - Newser
Why Fennec Pharmaceuticals Inc. stock is popular among millennialsMarket Weekly Review & Daily Volume Surge Signals - Newser
(FRX) Technical Pivots with Risk Controls (FRX:CA) - news.stocktradersdaily.com
Is Fennec Pharmaceuticals Inc. stock resilient to inflationInflation Watch & Fast Entry Momentum Alerts - Newser
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Can Fennec Pharmaceuticals Inc. stock attract ESG capital inflows2025 Bull vs Bear & Technical Pattern Based Buy Signals - Newser
Stocks in play: Fennec Pharmaceuticals Inc. - The Globe and Mail
Fennec Pharmaceuticals Inc Announces Positive Results from PEDMARK® Trial in Japan - TradingView
Wedbush on Fennec Pharmaceuticals Latest Japan Trial Results - marketscreener.com
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power - Benzinga
Fennec Pharmaceuticals Inc. Announces Positive Topline Results from Investigator-Initiated Clinical Study of Pedmark®? in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Says its Phase 2/3 Trial of Pedmark in Japan Meets Primary Endpoint - MarketScreener
Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan - TipRanks
Fennec’s pediatric hearing protection drug shows positive results in Japan By Investing.com - Investing.com Australia
Fennec Pharmaceuticals Brief: Announcing "Positive" Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss - marketscreener.com
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss - The Manila Times
Is Fennec Pharmaceuticals Inc. (RV41) stock a buy before new product rolloutQuarterly Trade Report & Daily Stock Trend Reports - Newser
(FRX) Long Term Investment Analysis (FRX:CA) - news.stocktradersdaily.com
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) Price Target at $13.33 - Defense World
(FRX) Technical Data (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - The Globe and Mail
Loss-Making Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Expected To Breakeven In The Medium-Term - Yahoo Finance
Trend Tracker for (FRX) (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals highlights cisplatin ototoxicity risks - Traders Union
(FENC) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Why Some Analysts Are Raising Price Targets on Silkflex Polymers India LimitedStochastic Oscillator Alerts & Capital Efficiency Improvement - earlytimes.in
(FRX) Strategic Investment Report (FRX:CA) - news.stocktradersdaily.com
Fennec Pharmaceuticals Completes Full Debt Redemption, Strengthening Financial Position - MSN
Is Fennec Pharmaceuticals Inc. (RV41) stock attractive post correctionTrade Volume Report & Consistent Profit Focused Trading Strategies - newser.com
How Fennec Pharmaceuticals Inc. (RV41) stock performs in volatility spikesWatch List & Daily Entry Point Trade Alerts - newser.com
Will Fennec Pharmaceuticals Inc. stock benefit from commodity pricesJuly 2025 Sentiment & Free Risk Controlled Daily Trade Plans - newser.com
How Fennec Pharmaceuticals Inc. (RV41) stock trades pre earningsJuly 2025 Action & AI Enhanced Trading Alerts - newser.com
What dividend safety score for Fennec Pharmaceuticals Inc. stockJuly 2025 Fed Impact & High Yield Stock Recommendations - newser.com
Southpoint Capital Advisors LP sells Fennec Pharmaceuticals shares By Investing.com - Investing.com Nigeria
Southpoint Capital Advisors LP sells Fennec Pharmaceuticals shares - Investing.com India
Fennec Pharmaceuticals Closes $5M Private Offering in Canada - MSN
Why Fennec Pharmaceuticals Inc. (RV41) stock is favored by hedge fundsPortfolio Risk Report & Real-Time Market Trend Scan - newser.com
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fennec Pharmaceuticals Inc Stock (FENC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Southpoint Capital Advisors LP | 10% Owner |
Nov 14 '25 |
Sale |
8.00 |
160,100 |
1,280,432 |
3,850,000 |
| Southpoint Capital Advisors LP | 10% Owner |
Nov 17 '25 |
Sale |
8.79 |
85,918 |
755,193 |
3,764,082 |
| Raykov Rosty | Director |
Nov 05 '25 |
Sale |
8.10 |
10,000 |
81,000 |
82,318 |
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):